Review





Similar Products

93
Sino Biological human ape1 apex1 cdna
Human Ape1 Apex1 Cdna, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ape1 apex1 cdna/product/Sino Biological
Average 93 stars, based on 1 article reviews
human ape1 apex1 cdna - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

93
Proteintech 357 ape1 ref 1
357 Ape1 Ref 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/357 ape1 ref 1/product/Proteintech
Average 93 stars, based on 1 article reviews
357 ape1 ref 1 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

93
Proteintech ape1 ref 1
<t>Expression</t> <t>of</t> <t>APE1/Ref-1</t> in Tumor Tissues of Patients with CRC ( A ) Flowchart illustrating the case screening process. ( B ) Representative images demonstrating APE1/Ref-1 expression assessed through IHC staining, with black horizontal lines indicating 200 μm. The red arrows denote specific locations that exemplify the range of APE1/Ref-1 expression. The accompanying histogram depicts the distribution of tumor stage and differentiation levels corresponding to each intensity of APE1/Ref-1 staining. ( C ) Visualization of patient baseline characteristics alongside APE1/Ref-1 IHC staining intensity, organized according to the American Joint Committee on Cancer (AJCC) stage. Abbreviations: AC: Ascending colon; TC: Transverse colon; DC: Descending colon; SC: Sigmoid colon. ( D ) A percentage stacked histogram illustrating the distribution of APE1/Ref-1 IHC staining intensity across various stages and degrees of differentiation. The category classified as “Poor” encompasses poorly differentiated adenocarcinoma, medullary carcinoma, and signet-ring cell carcinoma. Abbreviations: MC: Medullary carcinoma; SC: Signet-ring cell carcinoma; MA: Mucinous adenocarcinoma. E - F . Violin plots depicting the expression levels of APE1/Ref-1 in both tumor and normal tissues in TCGA database. G - H . Differential expression of APE1/Ref-1 was verified by IHC staining, with black horizontal lines indicating 200 μm. Normol, n = 3. Tumor, n = 176
Ape1 Ref 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ape1 ref 1/product/Proteintech
Average 93 stars, based on 1 article reviews
ape1 ref 1 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

94
Proteintech ape1 ref
<t>Expression</t> <t>of</t> <t>APE1/Ref-1</t> in Tumor Tissues of Patients with CRC ( A ) Flowchart illustrating the case screening process. ( B ) Representative images demonstrating APE1/Ref-1 expression assessed through IHC staining, with black horizontal lines indicating 200 μm. The red arrows denote specific locations that exemplify the range of APE1/Ref-1 expression. The accompanying histogram depicts the distribution of tumor stage and differentiation levels corresponding to each intensity of APE1/Ref-1 staining. ( C ) Visualization of patient baseline characteristics alongside APE1/Ref-1 IHC staining intensity, organized according to the American Joint Committee on Cancer (AJCC) stage. Abbreviations: AC: Ascending colon; TC: Transverse colon; DC: Descending colon; SC: Sigmoid colon. ( D ) A percentage stacked histogram illustrating the distribution of APE1/Ref-1 IHC staining intensity across various stages and degrees of differentiation. The category classified as “Poor” encompasses poorly differentiated adenocarcinoma, medullary carcinoma, and signet-ring cell carcinoma. Abbreviations: MC: Medullary carcinoma; SC: Signet-ring cell carcinoma; MA: Mucinous adenocarcinoma. E - F . Violin plots depicting the expression levels of APE1/Ref-1 in both tumor and normal tissues in TCGA database. G - H . Differential expression of APE1/Ref-1 was verified by IHC staining, with black horizontal lines indicating 200 μm. Normol, n = 3. Tumor, n = 176
Ape1 Ref, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ape1 ref/product/Proteintech
Average 94 stars, based on 1 article reviews
ape1 ref - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology anti ape1
<t>Expression</t> <t>of</t> <t>APE1/Ref-1</t> in Tumor Tissues of Patients with CRC ( A ) Flowchart illustrating the case screening process. ( B ) Representative images demonstrating APE1/Ref-1 expression assessed through IHC staining, with black horizontal lines indicating 200 μm. The red arrows denote specific locations that exemplify the range of APE1/Ref-1 expression. The accompanying histogram depicts the distribution of tumor stage and differentiation levels corresponding to each intensity of APE1/Ref-1 staining. ( C ) Visualization of patient baseline characteristics alongside APE1/Ref-1 IHC staining intensity, organized according to the American Joint Committee on Cancer (AJCC) stage. Abbreviations: AC: Ascending colon; TC: Transverse colon; DC: Descending colon; SC: Sigmoid colon. ( D ) A percentage stacked histogram illustrating the distribution of APE1/Ref-1 IHC staining intensity across various stages and degrees of differentiation. The category classified as “Poor” encompasses poorly differentiated adenocarcinoma, medullary carcinoma, and signet-ring cell carcinoma. Abbreviations: MC: Medullary carcinoma; SC: Signet-ring cell carcinoma; MA: Mucinous adenocarcinoma. E - F . Violin plots depicting the expression levels of APE1/Ref-1 in both tumor and normal tissues in TCGA database. G - H . Differential expression of APE1/Ref-1 was verified by IHC staining, with black horizontal lines indicating 200 μm. Normol, n = 3. Tumor, n = 176
Anti Ape1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ape1/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
anti ape1 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

94
Novus Biologicals ape1 ref 1 antibody mouse monoclonal
<t>Expression</t> <t>of</t> <t>APE1/Ref-1</t> in Tumor Tissues of Patients with CRC ( A ) Flowchart illustrating the case screening process. ( B ) Representative images demonstrating APE1/Ref-1 expression assessed through IHC staining, with black horizontal lines indicating 200 μm. The red arrows denote specific locations that exemplify the range of APE1/Ref-1 expression. The accompanying histogram depicts the distribution of tumor stage and differentiation levels corresponding to each intensity of APE1/Ref-1 staining. ( C ) Visualization of patient baseline characteristics alongside APE1/Ref-1 IHC staining intensity, organized according to the American Joint Committee on Cancer (AJCC) stage. Abbreviations: AC: Ascending colon; TC: Transverse colon; DC: Descending colon; SC: Sigmoid colon. ( D ) A percentage stacked histogram illustrating the distribution of APE1/Ref-1 IHC staining intensity across various stages and degrees of differentiation. The category classified as “Poor” encompasses poorly differentiated adenocarcinoma, medullary carcinoma, and signet-ring cell carcinoma. Abbreviations: MC: Medullary carcinoma; SC: Signet-ring cell carcinoma; MA: Mucinous adenocarcinoma. E - F . Violin plots depicting the expression levels of APE1/Ref-1 in both tumor and normal tissues in TCGA database. G - H . Differential expression of APE1/Ref-1 was verified by IHC staining, with black horizontal lines indicating 200 μm. Normol, n = 3. Tumor, n = 176
Ape1 Ref 1 Antibody Mouse Monoclonal, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ape1 ref 1 antibody mouse monoclonal/product/Novus Biologicals
Average 94 stars, based on 1 article reviews
ape1 ref 1 antibody mouse monoclonal - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

90
Proteostasis Therapeutics ref/ape1
<t>Expression</t> <t>of</t> <t>APE1/Ref-1</t> in Tumor Tissues of Patients with CRC ( A ) Flowchart illustrating the case screening process. ( B ) Representative images demonstrating APE1/Ref-1 expression assessed through IHC staining, with black horizontal lines indicating 200 μm. The red arrows denote specific locations that exemplify the range of APE1/Ref-1 expression. The accompanying histogram depicts the distribution of tumor stage and differentiation levels corresponding to each intensity of APE1/Ref-1 staining. ( C ) Visualization of patient baseline characteristics alongside APE1/Ref-1 IHC staining intensity, organized according to the American Joint Committee on Cancer (AJCC) stage. Abbreviations: AC: Ascending colon; TC: Transverse colon; DC: Descending colon; SC: Sigmoid colon. ( D ) A percentage stacked histogram illustrating the distribution of APE1/Ref-1 IHC staining intensity across various stages and degrees of differentiation. The category classified as “Poor” encompasses poorly differentiated adenocarcinoma, medullary carcinoma, and signet-ring cell carcinoma. Abbreviations: MC: Medullary carcinoma; SC: Signet-ring cell carcinoma; MA: Mucinous adenocarcinoma. E - F . Violin plots depicting the expression levels of APE1/Ref-1 in both tumor and normal tissues in TCGA database. G - H . Differential expression of APE1/Ref-1 was verified by IHC staining, with black horizontal lines indicating 200 μm. Normol, n = 3. Tumor, n = 176
Ref/Ape1, supplied by Proteostasis Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ref/ape1/product/Proteostasis Therapeutics
Average 90 stars, based on 1 article reviews
ref/ape1 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Expression of APE1/Ref-1 in Tumor Tissues of Patients with CRC ( A ) Flowchart illustrating the case screening process. ( B ) Representative images demonstrating APE1/Ref-1 expression assessed through IHC staining, with black horizontal lines indicating 200 μm. The red arrows denote specific locations that exemplify the range of APE1/Ref-1 expression. The accompanying histogram depicts the distribution of tumor stage and differentiation levels corresponding to each intensity of APE1/Ref-1 staining. ( C ) Visualization of patient baseline characteristics alongside APE1/Ref-1 IHC staining intensity, organized according to the American Joint Committee on Cancer (AJCC) stage. Abbreviations: AC: Ascending colon; TC: Transverse colon; DC: Descending colon; SC: Sigmoid colon. ( D ) A percentage stacked histogram illustrating the distribution of APE1/Ref-1 IHC staining intensity across various stages and degrees of differentiation. The category classified as “Poor” encompasses poorly differentiated adenocarcinoma, medullary carcinoma, and signet-ring cell carcinoma. Abbreviations: MC: Medullary carcinoma; SC: Signet-ring cell carcinoma; MA: Mucinous adenocarcinoma. E - F . Violin plots depicting the expression levels of APE1/Ref-1 in both tumor and normal tissues in TCGA database. G - H . Differential expression of APE1/Ref-1 was verified by IHC staining, with black horizontal lines indicating 200 μm. Normol, n = 3. Tumor, n = 176

Journal: Cancer Cell International

Article Title: APX3330 reverses the immunosuppressive tumor microenvironment during colorectal carcinogenesis

doi: 10.1186/s12935-026-04176-8

Figure Lengend Snippet: Expression of APE1/Ref-1 in Tumor Tissues of Patients with CRC ( A ) Flowchart illustrating the case screening process. ( B ) Representative images demonstrating APE1/Ref-1 expression assessed through IHC staining, with black horizontal lines indicating 200 μm. The red arrows denote specific locations that exemplify the range of APE1/Ref-1 expression. The accompanying histogram depicts the distribution of tumor stage and differentiation levels corresponding to each intensity of APE1/Ref-1 staining. ( C ) Visualization of patient baseline characteristics alongside APE1/Ref-1 IHC staining intensity, organized according to the American Joint Committee on Cancer (AJCC) stage. Abbreviations: AC: Ascending colon; TC: Transverse colon; DC: Descending colon; SC: Sigmoid colon. ( D ) A percentage stacked histogram illustrating the distribution of APE1/Ref-1 IHC staining intensity across various stages and degrees of differentiation. The category classified as “Poor” encompasses poorly differentiated adenocarcinoma, medullary carcinoma, and signet-ring cell carcinoma. Abbreviations: MC: Medullary carcinoma; SC: Signet-ring cell carcinoma; MA: Mucinous adenocarcinoma. E - F . Violin plots depicting the expression levels of APE1/Ref-1 in both tumor and normal tissues in TCGA database. G - H . Differential expression of APE1/Ref-1 was verified by IHC staining, with black horizontal lines indicating 200 μm. Normol, n = 3. Tumor, n = 176

Article Snippet: The primary antibody utilized was APE1/Ref-1 (Proteintech, IL, USA, #10203-1-AP, dilution 1:200).

Techniques: Expressing, Immunohistochemistry, Staining, Quantitative Proteomics

APE1/Ref-1 Redox Function Affects Immunosuppressive TME ( A ) Correlation between APE1/Ref-1 expression and the infiltration of MDSCs and CD8 + T cell analyzed within the TCGA database. ( B ) Representative IHC image of high (upper panel) or low (lower panel) APE1/Ref-1 expression. C - F . mIHC staining reveals the infiltration of immune cells in paraffin-embedded tumor tissues from CRC patients, categorized by high APE1/Ref-1 expression (left panel) and low APE1/Ref-1 expression (right panel), along with corresponding statistical analyses ( D - F ). Human PMN-MDSC are defined as CD11B + CD14 − 29,30 . The white horizontal line in the images denotes 200 μm. G . Visualization of luminex liquid suspension chip detection, where the interior of the circle indicates the inhibitory effect of the drug on cytokine expression, while the exterior indicates a promoting effect. The length of the fan segments represents the magnitude of fold change (FC), quantified as log2(FC) following drug treatment; the color of the segments corresponds to the P value, with gray indicating a lack of statistical significance. H - I . Assessment of alterations in the expression levels of tumor necrosis factor-α (TNF-α, H ) and CXCL1 ( I ) subsequent to APX3330 treatment in HT-29

Journal: Cancer Cell International

Article Title: APX3330 reverses the immunosuppressive tumor microenvironment during colorectal carcinogenesis

doi: 10.1186/s12935-026-04176-8

Figure Lengend Snippet: APE1/Ref-1 Redox Function Affects Immunosuppressive TME ( A ) Correlation between APE1/Ref-1 expression and the infiltration of MDSCs and CD8 + T cell analyzed within the TCGA database. ( B ) Representative IHC image of high (upper panel) or low (lower panel) APE1/Ref-1 expression. C - F . mIHC staining reveals the infiltration of immune cells in paraffin-embedded tumor tissues from CRC patients, categorized by high APE1/Ref-1 expression (left panel) and low APE1/Ref-1 expression (right panel), along with corresponding statistical analyses ( D - F ). Human PMN-MDSC are defined as CD11B + CD14 − 29,30 . The white horizontal line in the images denotes 200 μm. G . Visualization of luminex liquid suspension chip detection, where the interior of the circle indicates the inhibitory effect of the drug on cytokine expression, while the exterior indicates a promoting effect. The length of the fan segments represents the magnitude of fold change (FC), quantified as log2(FC) following drug treatment; the color of the segments corresponds to the P value, with gray indicating a lack of statistical significance. H - I . Assessment of alterations in the expression levels of tumor necrosis factor-α (TNF-α, H ) and CXCL1 ( I ) subsequent to APX3330 treatment in HT-29

Article Snippet: The primary antibody utilized was APE1/Ref-1 (Proteintech, IL, USA, #10203-1-AP, dilution 1:200).

Techniques: Expressing, Staining, Luminex, Suspension